Cisbio Bioassays has introduced six multimode cell lines to its expanding Tag-lite cellular platform.
The multimode cell lines enable researchers to investigate the biological complexity of cell membrane receptors using the same cellular material, making Tag-lite a complete drug discovery solution for GPCR studies.
In addition, five new fluorescent ligands, including ones for GABA-B and Grehlin receptor binding assays, have been added to enhance the Tag-lite platform, bringing the current number of ligands to 18.
Tag-lite is a non-radioactive, cell-based technological platform for cell surface receptor study and screening.
Membrane receptors, in particular GPCRs, are major therapeutic targets in pharmaceutical research as they are involved in every aspect of human physiology.
Cisbio Bioassays developed the Tag-lite platform to provide a multi-angle investigational tool that addresses their structure and function, from ligand binding and dimerisation to second messengers and ERK phosphorylation.
Tag-lite multimode cell lines now enable this analysis using the same cellular material, eliminating the need for researchers to develop and qualify their own cells for multiple assays.
Tag-lite cell lines released include, in particular, important GPCR targets such as CXCR4, as well as other chemokine receptors and cholecystokinin receptors.
The cell lines have all been validated with HTRF reagents and kits for receptor ligand binding assays, receptor homodimerisation assays, functional assays (Cellulerk) and second messenger accumulation assays (cAMP and IP-One).
The Tag-lite platform's growing catalogue of ligands, plasmids, cell lines, binding kits and assays enable scientists to investigate and screen using one solution.
In addition, Cisbio Bioassays offers custom labelling and full assay development services for dimerisation and binding.
